Valneva SE
As of Oct 22, 2026, Valneva is in Stage 1, the basing phase, now in week 9 (since Aug 24, 2026). It closed at $5.36, 55.3% below its 52-week high and below its 200-day average, which is falling.
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is VALN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
VALN among Biotechnology345th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …345 | VALN | Stage 1 · wk 9 | 25 | −15.6% |
Valneva: quick answers
What stage is Valneva in?
As of Oct 22, 2026, Valneva (VALN) is in Stage 1, the basing phase. It entered Stage 1 on Aug 24, 2026 and is in week 9. What the four stages mean
Is Valneva in an uptrend?
Not yet. Valneva is in Stage 1, a base that can come before an uptrend. It trades 22.9% below its 200-day average, which is falling.
How far is Valneva from its 52-week high?
Valneva closed at $5.36 on Oct 22, 2026, 55.3% below its 52-week high of $11.99. Its 52-week low is $4.78.
How has Valneva performed over the past year?
As of Oct 22, 2026, Valneva is down 45.7% over the past year and down 40.1% so far in 2026.
Which sector and industry is Valneva in?
Valneva is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.